Research Allowance Payout Germany 2026

The Research Allowance payout in Germany works differently from a classic funding grant. No money flows directly into the account after project approval; instead, a tax offsetting mechanism with a genuine refund effect applies. For founders, CFOs, and R&D leads in SMEs, understanding this mechanism is decisive in order to align liquidity planning and the tax process cleanly with one another.

What is the Research Allowance and who is entitled to it?

The Research Allowance is the central tax-based research funding instrument in Germany. It causes no dilution, triggers no repayment, and can be combined with grants, VC, or bank financing. The legal basis is the Research Allowance Act (FZulG), most recently expanded by the Growth Opportunities Act (March 2024) and the Act for a Tax-Based Immediate Investment Program (July 2025).

Legal basis: The Research Allowance Act (FZulG)

The FZulG governs entitlement, the assessment base, and the assessment of the allowance. In addition, the BMF circulars on the Research Allowance apply, as well as the practice of the BSFZ – the Certification Body for the Research Allowance (Bescheinigungsstelle Forschungszulage), which acts as the technical approval authority. Since March 2024, the funding rate and the catalog of eligible costs have been expanded; since July 2025, a higher funding ceiling applies from 2026.

Which companies can apply for the Research Allowance?

Eligible applicants are taxable companies of all legal forms that are registered for tax purposes in Germany and carry out eligible R&D. No minimum profit is required. Startups, biotech companies, and deep-tech SMEs in particular benefit, because the payout remains possible as a tax refund even in case of a loss.

Typical constellations relevant to applications:

• Software and AI with a degree of technological uncertainty
• Biotech and pharma with experimental development
• Automotive, mechanical engineering, climate and energy technology with systematic R&D

How high is the Research Allowance in Germany?

Funding rate and assessment base

The Research Allowance assessment base comprises wage-tax-liable R&D personnel costs of a company's own employees that are directly allocated to a certified project. Since March 2024, certain costs for depreciable movable assets as well as a higher share for contract research are additionally eligible. SMEs qualify for the increased funding rate of 35%, large companies for 25%.

For external research, note: it is not the full invoice that is applied. Only the legally defined share of the remunerated costs is eligible – higher since 2024 than before. Contracts and statements of work should be cleanly documented early.

Worked example, AI startup (10 people): €800,000 eligible R&D personnel costs × 35% = €280,000 Research Allowance. If the assessed corporate income tax is only €70,000, then €210,000 is paid out as a tax refund.

Maximum funding amount from January 1, 2026

From January 1, 2026, the maximum Research Allowance that can be assessed is up to €3 million per fiscal year. This increase goes back to the tax-based immediate investment program of July 2025. Older ceilings from the period before 2024 are no longer relevant for current planning.

According to OECD data on tax-based R&D funding, following the 2024–2025 reforms Germany is among the most competitive locations for tax-based research funding in Europe.

How does the payout of the Research Allowance work?

The most common misconception regarding the Research Allowance payout in Germany: after a positive BSFZ certificate, money flows immediately. That is not true. The BSFZ is only the technical approval step. The financial effect arises only with the separate application to the tax office via ELSTER and the subsequent tax assessment.

No direct payout to the business account

There is no down payment and no advance payment. The tax office assesses the allowance only after receipt of the application as part of the tax assessment. The Research Allowance is not a short-term cash substitute, but a predictable tax-based inflow without equity dilution, without typical bank collateral, and without project-related fund-draw logic.

Offsetting against income tax or corporate income tax

The assessed Research Allowance is fully offset against the next assessed income tax or corporate income tax. For corporations, the offsetting of the Research Allowance against corporate income tax is the standard case. For partnerships or sole proprietorships, the offsetting takes place as part of the income tax return.

The process in practice:

• Submit the BSFZ application for the R&D project
• After certification: document eligible costs per fiscal year
• File the Research Allowance application via ELSTER with the tax office
• After tax assessment: offsetting against the tax liability

Payout as a tax refund when the tax burden is exceeded

If the assessed allowance exceeds the actual tax burden, the tax office pays out the surplus. This makes the Research Allowance payout in case of a loss especially valuable for growth companies.

Worked example, mechanical engineering SME: €1.2 million in own R&D wages + €400,000 eligible contract research × 35% = €560,000 Research Allowance. Assessed tax: €180,000. Result: €380,000 in tax refund is transferred.

When does the tax office pay out the Research Allowance?

The decisive trigger is not the BSFZ certificate alone, but the tax assessment for the relevant year. Delayed annual financial statements directly cost months of liquidity here.

Step by step: From application to payout

The R&D project is first submitted to the BSFZ – Certification Body for the Research Allowance. The BSFZ examines whether basic research, industrial research, or experimental development in the tax sense is present.

Key documents:

• BSFZ certificate per project
• Time and activity records of the R&D personnel
• Payroll documents, project lists, and contract documents
• Evidence on contract research and the assets used
• 20% overhead lump sum on the remaining eligible expenses (from 2026 for projects starting after December 31, 2025, immediate investment program)

After submission via ELSTER, the tax office issues a Research Allowance assessment notice. The payout takes place as part of the next tax assessment – not in isolation from it.

Typical timeframe and possible delays

In well-organized structures, a payout a few months after submission of the tax return is realistic. However, a time lag of up to 12 months is not unusual – caused by unclear project demarcation, missing personnel documentation, or queries between the tax office and the tax department.

For predictable results, a fixed annual calendar is advisable: apply to the BSFZ early, record costs monthly, document technical uncertainties on an ongoing basis, and file the tax return immediately after the annual financial statements.

The Research Allowance and tax liability: Is the funding tax-free?

Is a Research Allowance tax-free?

Yes – the Research Allowance is tax-free within the meaning of the FZulG. It is not treated as regular business income and is not subject again to income tax or corporate income tax. It reduces the assessed tax and, in case of a surplus, is paid out as a refund – without any additional tax burden on this amount.

Accounting treatment: How the Research Allowance is correctly recorded

The accounting treatment depends on the legal form and the accounting standard. What is relevant is the accrual-based recognition of the claim as well as the correct linkage to tax expense and refund receivable. With IFRS reporting or a funding mix, the classification should be coordinated early with the tax advisor and the auditor.

Avoiding common mistakes in the Research Allowance payout

Many delays arise not because of a lack of innovative merit, but because of weak documentation. The Research Allowance does not fund general product development, but systematic R&D with technological risk. Routine adjustments, customer customizing, or market-oriented releases lead to queries and reductions.

Mistakes in the application to the tax office via ELSTER

Typical sources of error in the ELSTER application:

• Diverging annual figures between HR, accounting, and the tax department
• Missing separation of funded and non-funded periods
• Lump-sum expense estimates without time logic
• Unclear contractual situation for contract research

Sensible countermeasures:

• A uniform project code for HR, finance, and R&D
• Monthly time recording instead of annual reconstruction
• Short technical reports on uncertainties and iterations
• Contract review for external research before the project start

According to its own statements, BioNTech established internal R&D documentation processes early on that enabled a clean separation between eligible basic research and regulatory development work – an approach that can be transferred directly to Research Allowance application practice.

What to do if the payout is delayed?

If the refund fails to materialize, first check the status of the procedure: Is the Research Allowance assessment notice available? Has the tax return been fully processed? Are there open queries from the tax office? After that, a structured submission of missing documents is advisable.

If longer delays are emerging, the financing should not be based solely on the expected refund. Companies such as TRUMPF systematically combine the Research Allowance with federal programs and other funding instruments – an approach that significantly reduces liquidity risks from processing delays.

Conclusion: How to get the maximum out of the Research Allowance

In 2026, the Research Allowance payout in Germany is a strategically predictable liquidity instrument without dilution and without a repayment obligation. SMEs calculate with a 35% funding rate, a ceiling of €3 million, and a process that closely interlocks the BSFZ certificate, cost documentation, and tax assessment. Those who cleanly document R&D personnel costs, evidence technological uncertainty, and file the corporate income tax or income tax return early achieve predictable tax refunds – year after year, repeatable, and without equity dilution.